Les Laboratoires Nutrition & Cardiometabolism (LNC), a Bordeaux, France-based expert in medical nutrition and metabolic diseases, completed a €3.5m second funding round.
The round was led by Seventure Partners, with participation from IRDI, GSO Capital, Aqui-Invest and existing shareholder EPI.
Led by co-founder and President Claude Vincent, LNC designs and develops medical nutrition products, tailored to meet the specific needs of patients suffering from metabolic diseases (diabetes, cardiovascular disease).
The funds will help the company conduct large scale clinical studies and then offer its products to pharmaceutical and industrial (licensing or acquisition) partners. These products target two strategic markets chosen by LNC, namely reducing cardiometabolic risk in patients with pre-diabetes syndrome (insulin
resistance, adipocyte dysfunction and metabolic disorders leading to cardiovascular disease) and perioperative nutrition for obese patients undergoing Bariatric surgery (insertion of a gastric band, sleeve, etc.).
LNC will also consider investment opportunities in companies or product portfolios, aimed at strengthening its market position.